About ViaeX Technologies
ViaeX Technologies is a company based in San Francisco (United States) founded in 2016 by Hudson Liao. ViaeX Technologies has raised $4.25 million across 2 funding rounds from investors including IndieBio. ViaeX Technologies operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter San Francisco, United States
- Founders Hudson Liao
-
Sectors
EnvironmentHealthcare Technology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$4.25 M (USD)
in 2 rounds
-
Latest Funding Round
$4 M (USD), Series A
Aug 18, 2017
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of ViaeX Technologies
ViaeX Technologies has successfully raised a total of $4.25M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $4 million completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ViaeX Technologies
ViaeX Technologies has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include IndieBio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are accelerated through IndieBio's focused programs.
|
Locked | Locked | Locked |
Investor details for ViaeX Technologies
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ViaeX Technologies
Investment portfolio details for ViaeX Technologies
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ViaeX Technologies
Detailed financials for ViaeX Technologies
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Viaex Technologies Comparisons
Peer comparison for ViaeX Technologies
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ViaeX Technologies
ViaeX Technologies operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of ViaeX Technologies
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Viaex Technologies
Complete news archive for ViaeX Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ViaeX Technologies
ViaeX Technologies was founded in 2016.
ViaeX Technologies is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
ViaeX Technologies is a funded company, having raised a total of $4.25M across 2 funding rounds to date.
ViaeX Technologies was founded in 2016 in San Francisco, United States, within the nanomaterials and filtration sector. Algorithms and chemistries are utilized to convert biodegradable chitosan biowaste into customized nanomaterials. These materials support applications in water purification, industrial separation, skincare, food and beverage filtration, and wound healing. Operations focus on cross-industry solutions for sustainable processing.
ViaeX Technologies's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
ViaeX Technologies has 1 investor. Key investors include IndieBio.